Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis

References

• Mesaeli N, Nakamura K, Zvaritch E, Dickie P, Dziak E, Krause K-H, Opas M, MacLennan DH, Michalak M. Calreticulin is essential for cardiac development. J Cell Biol. 1999;144(5):857–5. doi:10.1083/jcb.144.5.857.
   PubMed Web of Science ®Google Scholar
• Gelebart P, Opas M, Michalak M. Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol. 2005;37(2):260–266. doi:10.1016/j.biocel.2004.02.030.
   PubMed Web of Science ®Google Scholar
• Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor S-M, Michalak M, Murphy‐Ullrich JE. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2010;24:665–683. doi:10.1096/fj.09-145482.
   PubMed Web of Science ®Google Scholar
• Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L. eIF2α phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25(8):1375–1393. doi:10.1038/s41418-017-0044-9.
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJM, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. Embo J. 2012;31(5):1062–1079. doi:10.1038/emboj.2011.497.
   PubMed Web of Science ®Google Scholar
• Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G. Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14(10):1848–1850. doi:10.1038/sj.cdd.4402201.
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund A-C, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. Embo J. 2009;28(5):578–590. doi:10.1038/emboj.2009.1.
   PubMed Web of Science ®Google Scholar
• van Vliet AR, Giordano F, Gerlo S, Segura I, Van Eygen S, Molenberghs G, Rocha S, Houcine A, Derua R, Verfaillie T, et al. The ER stress sensor PERK coordinates ER-plasma membrane contact site formation through interaction with Filamin-A and F-Actin remodeling. Mol Cell. 2017;65(5):885–899 e886. doi:10.1016/j.molcel.2017.01.020.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97–111. doi:10.1038/nri.2016.107.
   PubMed Web of Science ®Google Scholar
• Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588. doi:10.3389/fimmu.2015.00588.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immuno Cancer. 2020;8(1):e000337. doi:10.1136/jitc-2019-000337.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. doi:10.1038/nm1523.
   PubMed Web of Science ®Google Scholar
• Brown GC, Neher JJ. Eaten alive! Cell death by primary phagocytosis: ‘phagoptosis’. Trends Biochem Sci. 2012;37(8):325–332. doi:10.1016/j.tibs.2012.05.002.
   PubMed Web of Science ®Google Scholar
• Gardai SJ, Xiao Y-Q, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell. 2003;115:13–23. doi:10.1016/S0092-8674(03)00758-X.
   PubMed Web of Science ®Google Scholar
• Kasikova L, Hensler M, Truxova I, Skapa P, Laco J, Belicova L, Praznovec I, Vosahlikova S, Halaska MJ, Brtnicky T. Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J Immuno Cancer. 2019;7(1):312. doi:10.1186/s40425-019-0781-z.
   PubMed Web of Science ®Google Scholar
• Peng RQ, Chen YB, Ding Y, Zhang R, Zhang X, Yu XJ, Zhou ZW, Zeng YX, Zhang XS. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol. 2010;16:2428–2434. doi:10.3748/wjg.v16.i19.2428.
   PubMed Web of Science ®Google Scholar
• Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, Cremer I, Kroemer G. Calreticulin expression: interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Oncoimmunology. 2016;5(7):e1177692. doi:10.1080/2162402X.2016.1177692.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C. Calreticulin expression in human non–small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res. 2016;76(7):1746–1756. doi:10.1158/0008-5472.CAN-15-1142.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood. 2016;128(26):3113–3124. doi:10.1182/blood-2016-08-731737.
   PubMed Web of Science ®Google Scholar
• Wemeau M, Kepp O, Tesnière A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010;1(12):e104. doi:10.1038/cddis.2010.82.
   PubMed Web of Science ®Google Scholar
• Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P, Bilkova P, Holubova M, Chen X, Mikyskova R, et al. Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica. 2019. doi:10.3324/haematol.2019.223933.
   PubMed Web of Science ®Google Scholar
• Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94. doi:10.1126/scitranslmed.3001375.
   PubMed Web of Science ®Google Scholar
• Chen J, Zheng D-X, Yu X-J, Sun H-W, Xu Y-T, Zhang Y-J, Xu J. Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. Oncoimmunology. 2019;8(11):e1652540. doi:10.1080/2162402X.2019.1652540.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Yamazaki T, Kroemer G. Linking cellular stress responses to systemic homeostasis. Nature Reviews Molecular Cell Biology. 2018;19(11):731–745. doi:10.1038/s41580-018-0068-0.
   PubMed Web of Science ®Google Scholar
• Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G. Anticancer effects of anti-CD47 immunotherapy in vivo. Oncoimmunology. 2019;8(3):1550619. doi:10.1080/2162402X.2018.1550619.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–299. doi:10.1016/j.cell.2009.05.045.
   PubMed Web of Science ®Google Scholar
• Martinek J, Wu TC, Cadena D, Banchereau J, Palucka K. Interplay between dendritic cells and cancer cells. Int Rev Cell Mol Biol. 2019;348:179–215. doi:10.1016/bs.ircmb.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, Albu R-I, Defour J-P, Nivarthi H, Hug E. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood. 2019;133(25):2669–2681. doi:10.1182/blood-2018-09-874578.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao L, Loos F, Marty C, Xie W, Martins I, Lachkar S, Qu B, Waeckel-Énée E, Plo I, et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol Cell. 2019. doi:10.1016/j.molcel.2019.11.004.
   Web of Science ®Google Scholar
• Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, et al. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. Am J Hematol. 2016;91(2):211–219. doi:10.1002/ajh.24245.
   PubMed Web of Science ®Google Scholar
• Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med. 1998;188(12):2349–2356. doi:10.1084/jem.188.12.2349.
   PubMed Web of Science ®Google Scholar
• Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer J-P, Ho PY, McKenna KM, Cheshier S, Zhang M, Guo N, Gip P. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A. 2015;112(7):2145–2150. doi:10.1073/pnas.1424907112.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi:10.1056/NEJMoa1311347.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. doi:10.1056/NEJMoa1312542.
   PubMed Web of Science ®Google Scholar
• Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430. doi:10.1056/NEJMoa1716614.
   PubMed Web of Science ®Google Scholar
• Arshad N, Cresswell P. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J Biol Chem. 2018;293(25):9555–9569. doi:10.1074/jbc.RA118.002836.
   PubMed Web of Science ®Google Scholar
• Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol Oncol. 2016;9(1):45. doi:10.1186/s13045-016-0275-0.
   PubMed Web of Science ®Google Scholar
• Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127(10):1307–1316. doi:10.1182/blood-2015-09-671172.
   PubMed Web of Science ®Google Scholar
• Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R-I, Marty C, Gryshkova V, Defour J-P, Vertenoeil G, Ngo A. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127(10):1325–1335. doi:10.1182/blood-2015-11-681932.
   PubMed Web of Science ®Google Scholar
• Elf S, Abdelfattah NS, Chen E, Perales-Paton J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016;6(4):368–381. doi:10.1158/2159-8290.CD-15-1434.
   PubMed Web of Science ®Google Scholar
• Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, Villeval J-L, Raslova H, Kralovics R, Constantinescu SN. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317–1324. doi:10.1182/blood-2015-11-679571.
   PubMed Web of Science ®Google Scholar
• Balligand T, Achouri Y, Pecquet C, Gaudray G, Colau D, Hug E, Rahmani Y, Stroobant V, Plo I, Vainchenker W, et al. Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia. 2019. doi:10.1038/s41375-019-0538-1.
   PubMed Web of Science ®Google Scholar
• Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC. Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes. Leuk Lymphoma. 2018;59(4):973–977. doi:10.1080/10428194.2017.1359743.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–679. doi:10.1182/blood-2016-10-695940.
   PubMed Web of Science ®Google Scholar
• Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, Florescu N, Birrane G, Chen E, Mullally A. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 2018;131(7):782–786. doi:10.1182/blood-2017-08-800896.
   PubMed Web of Science ®Google Scholar
• Hong C, Zhang T, Gao XM. Recombinant murine calreticulin fragment 39-272 expands CD1d(hi)CD5+ IL-10-secreting B cells that modulate experimental autoimmune encephalomyelitis in C57BL/6 mice. Mol Immunol. 2013;55:237–246. doi:10.1016/j.molimm.2013.02.003.
   PubMed Web of Science ®Google Scholar
• Nam AS, Kim K-T, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. 2019;571(7765):355–360. doi:10.1038/s41586-019-1367-0.
   PubMed Web of Science ®Google Scholar